Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo

Ricardo A. Fernandes, Chaoran Li, Gang Wang, Xinbo Yang, Christina S. Savvides, Caleb R. Glassman, Shen Dong, Eric Luxenberg, Leah V. Sibener, Michael E. Birnbaum, Christophe Benoıst, Diane Mathis, K. Christopher GarcíaeLife 2020 · DOI

TL;DR

Researchers have developed a novel yeast display library to identify specific peptide agonists for visceral adipose tissue (VAT)-resident regulatory T (Treg) cells. They discovered a surrogate peptide that, when used in a vaccination strategy, expands these VAT-Treg cells, dampens inflammation, and improves metabolic health in mice, suggesting a new therapeutic avenue for metabolic diseases.

What Problem Does This Paper Address?

T regulatory (Treg) cells are crucial for maintaining immune homeostasis and preventing excessive inflammation. While their general suppressive functions are known, understanding the specific antigens that trigger and regulate different Treg cell populations, especially those residing in non-lymphoid tissues like visceral adipose tissue (VAT), has been a major challenge. This lack of specificity limits our ability to precisely manipulate Treg cell function for therapeutic purposes. The authors aim to address this by identifying specific peptide ligands that can activate VAT-Treg cells, thereby enabling targeted manipulation of their function to combat metabolic diseases, which are often linked to chronic low-grade inflammation in VAT.

Methods

The core of this study is the development and application of an A<sup>b</sup>-peptide yeast display library. This library allows for the unbiased screening of a vast repertoire of peptides presented by MHC class II molecules, enabling the identification of those recognized by specific T cell receptors (TCRs).

  1. Yeast Display Library Engineering: The researchers engineered a yeast display system where a peptide is fused to an antibody fragment (Ab) and expressed on the yeast surface. To improve its functionality and enable TCR recognition, the Ab component was evolved using error-prone PCR and selection with a known TCR.
  2. Affinity-Based Screening: The evolved yeast library was then screened using the TCR from a specific VAT-resident Treg cell clone (vTreg53). Through multiple rounds of selection, peptides that bind to the vTreg53 TCR were enriched.
  3. Surrogate Agonist Identification: Deep sequencing of the enriched yeast clones identified specific peptide sequences, termed surrogate agonists (SPs), that were recognized by the vTreg53 TCR.
  4. T Cell Activation Assays: Identified SPs were then tested for their ability to activate vTreg53 TCR-transduced Jurkat T cells and primary mouse Treg cells in vitro, measuring markers like CD69 and CD25 expression, and proliferation.
  5. In Vivo Studies: Promising SPs were administered to mice to assess their ability to expand VAT-Treg cells in vivo, both in spleen/lymph nodes and specifically in VAT.
  6. Metabolic and Inflammatory Assessments: Mice treated with SPs, particularly under high-fat diet (HFD) conditions, were assessed for VAT inflammation, insulin sensitivity, glucose tolerance, and plasma insulin levels.
  7. Transcriptional Analysis: RNA-sequencing was performed on VAT-Treg cells expanded by SPs to understand how antigen stimulation affects their gene expression profiles and to confirm they retained their characteristic VAT-Treg signature.
  8. Combination Therapy: The effect of combining SP treatment with anti-TNFα blockade was investigated to see if it could further enhance therapeutic outcomes.

Datasets

  • Yeast Display Library: A custom-built A<sup>b</sup>-peptide yeast display library containing up to 1 x 10<sup>9</sup> peptides was generated and used for screening.
  • RNA-Seq Data: Transcriptional profiling data was generated from sorted VAT-Treg cells and splenic/lymph node Treg cells from mice immunized with surrogate peptides.
  • Deep Sequencing Data: Data from the deep sequencing of the peptide-Ab yeast library after selection rounds was used to identify enriched peptide sequences.

Key Insights and Ideas

  • VAT-Treg cells have specific TCR recognition: The study demonstrates that VAT-resident Treg cells, like the vTreg53 clone, recognize specific peptide antigens, challenging the notion of Treg cells being solely broadly polyspecific.
  • Yeast display is a powerful tool for Treg TCR de-orphanization: The developed A<sup>b</sup>-peptide yeast display library proved effective in identifying cognate peptides for a specific Treg TCR, a notoriously difficult task.
  • Surrogate agonists can mimic endogenous ligands: The identified SPs, while not necessarily endogenous ligands, effectively activate and expand specific Treg populations, offering a practical alternative for therapeutic manipulation.
  • Targeting VAT-Tregs can improve metabolic health: Expanding VAT-Treg cells using SPs led to reduced VAT inflammation and improved insulin sensitivity in obese mice, highlighting the therapeutic potential of this approach.
  • Combination therapy enhances efficacy: Blocking TNFα alongside SP treatment further amplified the beneficial effects on VAT-Treg expansion and metabolic improvements.

Key Results

  • The authors successfully identified several surrogate agonist peptides (SPs) recognized by the vTreg53 TCR.
  • The SP "Fat1562" was particularly potent, inducing robust proliferation and activation of vTreg53 Treg cells in vitro.
  • In vivo, immunization with Fat1562 led to a significant expansion of transferred vTreg53 Treg cells, especially within the VAT (over 25-fold expansion).
  • Fat1562-expanded VAT-Treg cells maintained their characteristic VAT-Treg transcriptional signature.
  • In mice fed a high-fat diet, Fat1562 treatment, especially when combined with anti-TNFα blockade, significantly improved insulin sensitivity, promoted glucose tolerance, and reduced fasting insulin levels.
  • Fat1562 treatment also led to a reduction in pro-inflammatory macrophages and an increase in eosinophils in VAT.

Limitations and Future Work

  • Inability to identify endogenous ligand: Despite extensive efforts, the authors were unable to deorphanize the vTreg53 TCR with an endogenous antigen. They speculate this could be due to limitations in the yeast display system, the complexity of peptide presentation, or the low affinity of self-peptides.
  • Variability in endogenous Treg response: While Fat1562 could expand endogenous Treg populations, the specific TCRs expanded varied between individual mice, suggesting a degree of inherent variability in the immune response.
  • Future Directions: The authors suggest that SPs offer a viable alternative to self-antigens for promoting local, tissue-specific Treg expansion and immunosuppressive activity. Further research could focus on identifying SPs for other disease-relevant Treg populations and exploring their therapeutic potential in various inflammatory and metabolic conditions. The development of more refined screening methods to identify endogenous ligands remains an important goal.

Summary updated

Abstract

T regulatory (Treg) cells play vital roles in modulating immunity and tissue homeostasis. Their actions depend on TCR recognition of peptide-MHC molecules; yet the degree of peptide specificity of Treg-cell function, and whether Treg ligands can be used to manipulate Treg cell biology are unknown. Here, we developed an A<sup>b</sup>-peptide library that enabled unbiased screening of peptides recognized by a bona fide murine Treg cell clone isolated from the visceral adipose tissue (VAT), and identified surrogate agonist peptides, with differing affinities and signaling potencies. The VAT-Treg cells expanded in vivo by one of the surrogate agonists preserved the typical VAT-Treg transcriptional programs. Immunization with this surrogate, especially when coupled with blockade of TNFα signaling, expanded VAT-Treg cells, resulting in protection from inflammation and improved metabolic indices, including promotion of insulin sensitivity. These studies suggest that antigen-specific targeting of VAT-localized Treg cells could eventually be a strategy for improving metabolic disease.
BibTeX
@inproceedings{fernandes2020discovery,
  author = {Ricardo A. Fernandes and Chaoran Li and Gang Wang and Xinbo Yang and Christina S. Savvides and Caleb R. Glassman and Shen Dong and Eric Luxenberg and Leah V. Sibener and Michael E. Birnbaum and Christophe Benoıst and Diane Mathis and K. Christopher García},
  title = {{Discovery of surrogate agonists for visceral fat Treg cells that modulate metabolic indices in vivo}},
  booktitle = {eLife},
  year = {2020},
  doi = {10.7554/elife.58463},
}
Figure